Global Health Institute, University of Antwerp, Antwerp, Belgium.
Neurology Department, Yaoundé Central Hospital, Yaoundé, Cameroon.
Infect Dis Poverty. 2018 Dec 3;7(1):114. doi: 10.1186/s40249-018-0497-1.
A high epilepsy prevalence has been reported in several onchocerciasis-endemic villages along the Mbam and Sanaga river valleys in Cameroon, including Bilomo and Kelleng. We sought to determine the prevalence of epilepsy in these two villages following more than 13 years of community-directed treatment with ivermectin (CDTI).
Door-to-door surveys were performed on the entire resident population in the villages in August 2017 and January 2018. Epilepsy was diagnosed using a 2-step approach: administration of a standardized 5-item questionnaire followed by confirmation by a neurologist. Previously published diagnostic criteria for onchocerciasis-associated epilepsy (OAE) were used. Ov16 serology was done for children aged 7-10 years to assess onchocerciasis transmission. Findings were compared with previous data from these two villages.
A total of 1525 individuals (1321 in Bilomo and 204 in Kelleng) in 233 households were surveyed in both villages. The crude prevalence of epilepsy was 4.6% in Bilomo (2017) and 7.8% in Kelleng (2018), including 12 (15.6% of cases) persons with epilepsy (PWE) with nodding seizures. The age and sex-standardized prevalence in Kelleng decreased from 13.5% in 2004 to 9.3% in 2018 (P < 0.001). The median age of PWE shifted from 17 (IQR: 12-22) years to 24 (IQR: 20-30) years in Bilomo (P < 0.001); and slightly from 24 (IQR: 14-34) years to 28 (IQR: 21.25-36.75) years in Kelleng (P = 0.112). Furthermore, 47.6% of all tested children between 7 and 10 years had Ov16 antibodies.
There is a decrease in epilepsy prevalence after 13 years and more of CDTI in both villages. The age-shift observed in PWE suggests that ivermectin may prevent OAE in younger residents. Ov16 seropositivity in children indicates ongoing onchocerciasis transmission possibly due to suboptimal control measures. Our findings support the existence of OAE in Cameroon and highlight the need to strengthen onchocerciasis elimination programs.
在喀麦隆 Mbam 和 Sanaga 河谷的几个盘尾丝虫病流行村庄,包括 Bilomo 和 Kelleng,据报道癫痫患病率很高。我们试图在这两个村庄进行了 13 多年的社区定向治疗伊维菌素(CDTI)后,确定癫痫的患病率。
2017 年 8 月和 2018 年 1 月,我们对村庄的所有居民进行了逐户调查。使用两步法诊断癫痫:首先进行标准化的 5 项问卷调查,然后由神经科医生确认。使用以前发表的盘尾丝虫病相关癫痫(OAE)诊断标准。对 7-10 岁的儿童进行 Ov16 血清学检测,以评估盘尾丝虫病的传播情况。研究结果与这两个村庄以前的数据进行了比较。
在这两个村庄的 233 户家庭中,共有 1525 人(Bilomo 1321 人,Kelleng 204 人)接受了调查。Bilomo 的癫痫粗患病率为 4.6%(2017 年),Kelleng 为 7.8%(2018 年),包括 12 名(占病例的 15.6%)有癫痫发作的癫痫患者(PWE)。Kelleng 的年龄和性别标准化患病率从 2004 年的 13.5%降至 2018 年的 9.3%(P<0.001)。Bilomo 的 PWE 年龄中位数从 17 岁(IQR:12-22)岁变为 24 岁(IQR:20-30)岁(P<0.001);在 Kelleng 中,年龄中位数从 24 岁(IQR:14-34)岁略有变为 28 岁(IQR:21.25-36.75)岁(P=0.112)。此外,7-10 岁的所有受检儿童中,有 47.6%的儿童有 Ov16 抗体。
在两个村庄进行了 13 多年的 CDTI 后,癫痫患病率有所下降。PWE 年龄的变化表明,伊维菌素可能会预防年轻居民的 OAE。儿童 Ov16 血清阳性表明,可能由于控制措施不充分,盘尾丝虫病仍在传播。我们的研究结果支持喀麦隆存在 OAE,并强调需要加强盘尾丝虫病消除计划。